Gennery Andrew
Paediatric Immunology and Haematopoietic Stem Cell Transplantation, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK; Paediatric Immunology and Haematopoietic Stem Cell Transplantation, Great North Childrens' Hospital, Newcastle upon Tyne, UK.
F1000Res. 2015 Dec 16;4. doi: 10.12688/f1000research.7013.1. eCollection 2015.
Primary immunodeficiencies are rare, inborn errors that result in impaired, disordered or uncontrolled immune responses. Whilst symptomatic and prophylactic treatment is available, hematopoietic stem cell transplantation is an option for many diseases, leading to cure of the immunodeficiency and establishing normal physical and psychological health. Newborn screening for some diseases, whilst improving outcomes, is focusing research on safer and less toxic treatment strategies, which result in durable and sustainable immune function without adverse effects. New conditioning regimens have reduced the risk of hematopoietic stem cell transplantation, and new methods of manipulating stem cell sources should guarantee a donor for almost all patients. Whilst incremental enhancements in transplantation technique have gradually improved survival outcomes over time, some of these new applications are likely to radically alter our approach to treating primary immunodeficiencies.
原发性免疫缺陷是罕见的先天性疾病,会导致免疫反应受损、紊乱或失控。虽然有对症和预防性治疗方法,但造血干细胞移植是许多疾病的一种选择,可治愈免疫缺陷并建立正常的身心健康。对某些疾病进行新生儿筛查,在改善治疗效果的同时,正将研究重点放在更安全、毒性更小的治疗策略上,这些策略可产生持久且可持续的免疫功能而无不良影响。新的预处理方案降低了造血干细胞移植的风险,操纵干细胞来源的新方法应能确保几乎所有患者都有供体。随着时间的推移,移植技术的逐步改进逐渐提高了生存结果,其中一些新应用可能会从根本上改变我们治疗原发性免疫缺陷的方法。